Regular ArticleTumor Cell Nitric Oxide Inhibits Cell Growthin Vitro,but Stimulates Tumorigenesis and Experimental Lung Metastasisin Vivo
Abstract
Arginine-derived nitric oxide (NO) has been identified in some tumor cell lines and solid human tumors. The effect of tumor cell NO on tumor biology is poorly understood. The purpose of this study was to investigate the effect of NO production by EMT-6 murine breast cancer cells on tumor cell growthin vitroand subcutaneous tumor growth and experimental pulmonary metastasisin vivo.EMT-6 cells were incubated with endotoxin (LPS, 10 μg/ml) and interferon-γ (IFN, 50 U/ml), in the presence or absence of the NO synthase inhibitor, ω-nitro-L-arginine methyl ester (L-NAME, 2 mM), and NO production and cell number were assessed 24 hr later. EMT-6 cells were also treated overnight with LPS/IFN, in the presence or absence of L-NAME, washed and injected either subcutaneously in the dorsal flank (n= 40) or via the tail vein (n= 40) of syngeneic BALB/c mice. Two weeks following tumor cell injection, tumor size and number of pulmonary metastases were assessed. LPS/IFN stimulated NO production in EMT-6 cells and inhibited cell growthin vitroby 50%. L-NAME blocked LPS/IFN stimulation of NO production and restored cell growth to near control levels. When injected into BALB/c mice, LPS/IFN-stimulated tumor cells demonstrated a two-fold increase in subcutaneous tumor growth and experimental pulmonary metastases over control cells. L-NAME reduced tumor size and number of lung metastases to control levels, suggesting that tumor cell NO production was responsible for this effect. In summary, LPS/IFN-stimulated NO production in EMT-6 tumor cells inhibits tumor cell growthin vitro,yet paradoxically augments tumor growth and metastasisin vivo.
References (0)
Cited by (89)
Simultaneous imaging of hypochlorous acid and nitric oxide in live cells based on a dual-channel fluorescent probe
2021, Analytica Chimica ActaBoth reactive oxygen species (ROS) and reactive nitrogen species (RNS) are inevitably produced during normal human metabolism. Various ROS and RNS together form tangled networks that play important roles in many physiological and pathological processes. Here we used 1,8-naphthalene diamine as a reactive group to develop a fluorescent probe, N-[2-(6-phenylethynyl)quinolinylmethyl]-1,8-diamino naphthalene (QBN), for HOCl and NO. QBN showed a “turn-on” fluorescent response at 464 nm to HOCl in the range of 0–75 μM with rapid responding time (10 s) and detection limit (0.11 ± 0.03 μM). Furthermore, a “turn-on” fluorescent responses at 512 nm to NO in the range of 0–40 μM with responding time (20 s) and detection limit (25.7 ± 3.4 nM) was found. The response mechanisms of QBN to HOCl and NO were discussed based on mass analysis of the different products. The dual-channel probe was then successfully applied for simultaneous imaging of both exogenous and endogenous HOCl and NO in live cells.
Mitochondrial NOS1 suppresses apoptosis in colon cancer cells through increasing SIRT3 activity
2019, Biochemical and Biophysical Research CommunicationsCitation Excerpt :It has been reported that NO regulated various cancer processes, including angiogenesis, apoptosis, invasion and metastasis [2,3]. However, there is considerable controversy and confusion in understanding its role in cancer biology [4,5]. Studies have shown that it has the function of inhibiting tumors and promoting tumors, depending on its concentration, location and time [6].
Previous studies have suggested that nitric oxide (NO) which is synthetized by nitric oxide synthase (NOS) is closely related to the carcinogenesis and progression of colon cancer. However, the precise physiopathological role of NO on colon cancer remains unclear, and a lot of related studies focused on NOS2 and NOS3, but little on NOS1. Here, stable overexpression NOS1 of colon cancer cells were constructed to investigate whether NOS1 plays a special role in colon cancer. We observed that NOS1 protein was presented in mitochondria. Both the basal and cisplatin-induced mitochondrial superoxide were inhibited by NOS1, and the cisplatin-induced apoptosis was also inhibited by NOS1. Geldanamycin, a Hsp90 N-terminal inhibitor, was able to impede NOS1 translocation into mitochondria and reverse NOS1-induced apoptosis resistance. Importantly, SIRT3 activity was enhanced by NOS1, which contributes to the low level of mitochondrial superoxide and apoptosis resistance. Our data suggest a link between NOS1 and apoptosis resistance in colon cancer cells through mtNOS1-SIRT3-SOD2 axis. Furthermore, NOS1-induced apoptosis resistance could be reversed by inhibiting mitochondrial translocation of NOS1.
Enzymes involved in tumor-driven angiogenesis: A valuable target for anticancer therapy
2019, Seminars in Cancer BiologyAngiogenesis plays a pivotal role in cancer progression and is required for tissue invasion and metastasis. Starting with Folkman’s initial observations in 1971, basic research continued to shed new molecular insight into this multifaceted process, leading to the development of several anti-angiogenic drugs. To date, anti-vascular endothelial growth factor monoclonal antibodies, such as bevacizumab and ramucirumab, and receptor tyrosine kinase inhibitors (e.g., sorafenib, sunitinib, regorafenib and axitinib) have had a profound impact on the way we treat patients with advanced cancer, providing in some cases unprecedented clinical benefit. The molecular mechanisms underlying tumor-driven angiogenesis have been explored extensively and have unveiled a number of potential clinically relevant targets, including several novel enzymes. In this review, we summarized the current strategies to target tumor-driven angiogenesis through the inhibition of relevant and selected classes of enzymes involved in this process.
Dual gene deficient models of Apc<sup>Min/+</sup> mouse in assessing molecular mechanisms of intestinal carcinogenesis
2018, Biomedicine and PharmacotherapyThe ApcMin/+ mouse, carrying an inactivated allele of the adenomatous polyposis coli (Apc) gene, is a widely used animal model of human colorectal tumorigenesis. While crossed with other gene knockout or knock-in mice, these mice possess advantages in investigation of human intestinal tumorigenesis. Intestinal tumor pathogenesis involves multiple gene alterations; thus, various double gene deficiency models could provide novel insights into molecular mechanisms of tumor biology, as well as gene-gene interactions involved in intestinal tumor development and assessment of novel strategies for preventing and treating intestinal cancer. This review discusses approximately 100 double gene deficient mice and their associated intestinal tumor development and progression phenotypes. The dual gene knockouts based on the Apc mutation background consist of inflammation and immune-related, cell cycle-related, Wnt/β-catenin signaling-related, tumor growth factor (TGF)-signaling-related, drug metabolism-related, and transcription factor genes, as well as some oncogenes and tumor suppressors. Future studies should focus on conditional or inducible dual or multiple mouse gene knockout models to investigate the molecular mechanisms underlying intestinal tumor development, as well as potential drug targets.
Application of the Apc<sup>Min/+</sup> mouse model for studying inflammation-associated intestinal tumor
2015, Biomedicine and PharmacotherapyChronic inflammatory diseases of the intestinal tract have been known to increase risk of developing a form of colorectal cancer known as inflammation-associated cancer. The roles of inflammation in tumor formation and development in ApcMin/+ mice have been broadly corroborated. The ApcMin/+ mouse model contains a point mutation in the adenomatous polyposis coli (Apc) gene and only develops intestinal precancerous lesions, the benign adenomas. Thus, it provides an excellent in vivo system to investigate the molecular events involved in the inflammatory process which may contribute to multistep tumorigenesis and carcinogenesis. Recent investigations that employ this model studied the effects of gene alterations, intestinal microorganisms, drugs, diet, exercise and sleep on the inflammatory process and tumor development, and revealed the mechanisms involved in the formation, promotion and carcinogenesis of adenomas with the background of inflammation. Herein, we focus our review on the application of the ApcMin/+ mouse model for studying inflammation-associated intestinal tumor and find that anti-inflammation is a possible strategy in combating intestinal tumor, but sometimes anti-inflammation cannot help reduce tumor burden. Moreover, various inflammation-related genes are involved in different mechanistic stages of tumor in ApcMin/+ mice and intricate regulatory effects of inflammation exist in the whole progression of intestinal tumor.
Insights into the diverse effects of nitric oxide on tumor biology
2014, Vitamins and HormonesAmong its many roles in cellular biology, nitric oxide (NO) has long been associated with cancers both as a protumorigenic and as an antitumorigenic agent. The dual nature of this signaling molecule in varied settings is attributable to its temporal and concentration-dependent effects that produce different phenotypes. The steady-state NO concentration within the cell is a balance between its rate of enzymatic synthesis from the three nitric oxide synthase (NOS) isoforms and consumption via numerous metabolic pathways and demonstrates strong dependence on the tissue oxygen concentration. NOS expression and NO production are often deregulated and associated with numerous types of cancers with dissimilar prognostic outcomes. NO influences several facets of tumor initiation and progression including DNA damage, chronic inflammation, angiogenesis, epithelial-mesenchymal transition, and metastasis, to name a few. The role of NO as an epigenetic modulator has also recently emerged and has potentially important mechanistic implications in regulating transcription of oncogenes and tumor-suppressor genes. NO-derived cellular adducts such as dinitrosyliron complexes and the formation of higher nitrogen oxides further alter its cellular behavior. Among anticancer strategies, the use of NOS as a prognostic biomarker and modulation of NO production for therapeutic benefit have gained importance over the past decade. Numerous NO-releasing drugs and NOS inhibitors have been evaluated in preclinical and clinical settings to arrest tumor growth. Taken together, NO affects various arms of cancer signaling networks. An overview of this complex interplay is provided in this chapter.